A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Université Claude Bernard Lyon 1 · Inserm · +36 more institutions
Abstract
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study ( NCT04328298 ). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and…
Citation impact
- FWCI
- 34.01
- Percentile
- 100%
- References
- 39
Authors
32- EBEmmanuel BachyCorresponding
Université Claude Bernard Lyon 1, Inserm, Hospices Civils de Lyon, Hôpital Lyon Sud, Centre International de Recherche en Infectiologie
- SLSteven Le Gouill
Institut Curie
- RDRoberta Di Blasi
Hôpital Saint-Louis
- PSPierre Sesques
Hospices Civils de Lyon
- GMGuillaume Manson
Centre Hospitalier Universitaire de Rennes
Topics & keywords
- Medicine
- Hazard ratio
- Cytokine release syndrome
- Internal medicine
- Propensity score matching
- Diffuse large B-cell lymphoma
- Gastroenterology
- Refractory (planetary science)
- Good health and well-being